Irbesartan

證據等級: L5

預測適應症: 10 個

Irbesartan: From Hypertension to Malignant Renovascular Hypertension

One-Sentence Summary

Irbesartan is an angiotensin II receptor blocker (ARB) used internationally to treat hypertension and diabetic nephropathy, with landmark Phase 3 evidence from the IDNT and RENAAL trials demonstrating renal protection in type 2 diabetes. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, with no clinical trials and no directly relevant publications currently identified for this specific indication, though strong ARB class-effect mechanistic rationale provides indirect support. The high prediction score (99.31%) reflects the precise alignment between Irbesartan’s RAAS-blocking mechanism and the pathophysiology of renovascular hypertension.

Quick Overview

Item	Content
Original Indication	Hypertension; Diabetic nephropathy (type 2 diabetes with proteinuria)
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.31%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, directly suppressing the renin-angiotensin-aldosterone system (RAAS). This inhibits angiotensin II-driven vasoconstriction, aldosterone secretion, renal sodium retention, and downstream organ fibrosis. While detailed MOA data from DrugBank was unavailable at the time of this report, Irbesartan’s ARB class pharmacology is well characterised in the international literature and clinical guidelines.

Malignant renovascular hypertension arises when renal artery stenosis triggers excessive RAAS activation, producing severely elevated blood pressure with rapid end-organ damage (hypertensive retinopathy, microangiopathic haemolytic anaemia, renal impairment). The mechanistic alignment between AT1 blockade and the RAAS overdrive central to this condition is highly compelling. Furthermore, Irbesartan’s established nephroprotective benefits in diabetic nephropathy — a condition also characterised by glomerular hypertension and RAAS dysregulation — provide indirect mechanistic support for applicability to renovascular pathology.

An important clinical caveat must be noted: ARBs carry a specific risk of precipitating acute kidney injury in bilateral renal artery stenosis or stenosis of a solitary functioning kidney, where glomerular filtration becomes critically dependent on angiotensin II-mediated efferent arteriolar tone. Malignant renovascular hypertension frequently involves this anatomical scenario. This risk–benefit complexity requires specialist nephrology evaluation and makes direct clinical investigation — rather than empirical use — the appropriate next step.

Clinical Trial Evidence

Currently no related clinical trials registered for Irbesartan in malignant renovascular hypertension.

Literature Evidence

Currently no directly relevant literature available for Irbesartan in malignant renovascular hypertension.

Australia Market Information

Irbesartan is not currently registered in the Australian Register of Therapeutic Goods (ARTG) and has no TGA-approved Product Information in Australia.

Australian clinicians seeking to use Irbesartan should note that it is widely approved in other jurisdictions (US FDA, EMA) and is available generically under brand names such as Avapro and Aprovel internationally. Any proposed use in Australia would require assessment under the TGA’s Authorised Prescriber or Special Access Scheme (SAS) pathways.

Safety Considerations

As Irbesartan has no ARTG registration, no TGA Product Information is available. Based on internationally recognised class-effect pharmacology of angiotensin receptor blockers, the following are key considerations relevant to the predicted indication:

Renal artery stenosis risk: ARBs may precipitate acute kidney injury in bilateral renal artery stenosis — a clinically critical risk given that renovascular disease is the aetiology of the target indication. Renal function and serum potassium must be monitored closely if use is considered.
Hyperkalaemia: Risk is heightened in patients with concurrent renal impairment or use of potassium-sparing agents.
Pregnancy: All ARBs are contraindicated in pregnancy (Pregnancy Category D); associated with foetal renal dysplasia and neonatal death.
First-dose hypotension: Risk of symptomatic hypotension in volume-depleted or salt-restricted patients, particularly relevant in hypertensive emergencies.

For comprehensive prescribing information, refer to the US FDA-approved label or EMA-approved Summary of Product Characteristics (SmPC) for Irbesartan.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a mechanistically compelling prediction — AT1 blockade directly addresses the RAAS overdrive driving malignant renovascular hypertension — the complete absence of clinical trial or publication evidence for this specific indication, combined with the well-recognised safety risk of ARBs in bilateral renovascular disease, means that clinical advancement cannot be recommended without prospective safety and efficacy data.

To proceed, the following is needed:

Retrieval of detailed MOA data from DrugBank (DB01029) to formally document mechanistic links and complete the S1 safety pre-assessment
TGA Product Information or international equivalent (FDA label / EMA SmPC) review to document warnings and contraindications for Australian context
Systematic review of ARB class evidence in renovascular hypertension (unilateral vs bilateral stenosis scenarios) to quantify indirect class-level support
Assessment of whether existing hypertensive nephropathy or malignant hypertension trials (e.g., IDNT subgroup analyses) include renovascular aetiologies
Case series or registry data on ARB use in malignant renovascular hypertension to establish preliminary safety signal
If evidence supports advancement: development of a prospective observational protocol or pilot RCT, with ethics approval via the Australian HREC system
Regulatory pathway assessment under TGA SAS Category B or Authorised Prescriber scheme for any proposed clinical investigation in Australia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.